Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022

被引：0

作者：

Link-Gelles, Ruth ^{[1
]}

Levy, Matthew E. ^{[2
]}

Gaglani, Manjusha ^{[3
,4
]}

Irving, Stephanie A. ^{[5
]}

Stockwell, Melissa ^{[6
,7
,8
]}

Dascomb, Kristin ^{[9
]}

DeSilva, Malini B. ^{[10
]}

Reese, Sarah E. ^{[2
]}

Liao, I-Chia ^{[3
]}

Ong, Toan C. ^{[11
]}

Grannis, Shaun J. ^{[12
,13
]}

McEvoy, Charlene ^{[10
]}

Patel, Palak ^{[1
]}

Klein, Nicola P. ^{[14
]}

Hartmann, Emily ^{[15
]}

Stenehjem, Edward ^{[9
]}

Natarajan, Karthik ^{[8
,16
]}

Naleway, Allison L. ^{[5
]}

Murthy, Kempapura ^{[3
]}

Rao, Suchitra ^{[11
]}

Dixon, Brian E. ^{[12
,17
]}

Kharbanda, Anupam B. ^{[18
]}

Akinseye, Akintunde ^{[2
]}

Dickerson, Monica ^{[1
]}

Lewis, Ned ^{[14
]}

Grisel, Nancy ^{[9
]}

Han, Jungmi ^{[16
]}

Barron, Michelle A. ^{[11
]}

Fadel, William F. ^{[12
,17
]}

Dunne, Margaret M. ^{[2
]}

Goddard, Kristin ^{[14
]}

Arndorfer, Julie ^{[9
]}

Konatham, Deepika ^{[3
]}

Valvi, Nimish R. ^{[12
]}

Currey, J. C. ^{[15
]}

Fireman, Bruce ^{[14
]}

Raiyani, Chandni ^{[3
]}

Zerbo, Ousseny ^{[14
]}

Sloan-Aagard, Chantel ^{[15
,19
]}

Ball, Sarah W. ^{[2
]}

Thompson, Mark G. ^{[1
]}

Tenforde, Mark W. ^{[1
]}

机构：

[1] CDC COVID 19 Emergency Response Team, Atlanta, GA 30333 USA

[2] Westat Corp, Rockville, MD USA

[3] Baylor Scott & White Hlth, Temple, TX USA

[4] Texas A&M Univ, Coll Med, Temple, TX 76508 USA

[5] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA

[6] Columbia Univ, Vagelos Coll Phys & Surg, Dept Pediat, Div Child & Adolescent Hlth, New York, NY 10027 USA

[7] Columbia Univ, Mailman Sch Publ Hlth, Dept Populat & Family Hlth, New York, NY USA

[8] New York Presbyterian Hosp, New York, NY USA

[9] Intermt Healthcare, Div Infect Dis & Clin Epidemiol, Salt Lake City, UT USA

[10] Hlth Partners Inst, Minneapolis, MN USA

[11] Univ Colorado, Sch Med, Anschutz Med Campus, Aurora, CO USA

[12] Regenstrief Inst Hlth Care, Ctr Biomed Informat, Indianapolis, IN USA

[13] Indiana Univ, Sch Med, Indianapolis, IN USA

[14] Kaiser Permanente Vaccine Study Ctr, Kaiser Permanente Northern Calif Div Res, Oakland, CA USA

[15] Paso Norte Hlth Informat Exchange, El Paso, TX USA

[16] Columbia Univ, Irving Med Ctr, Dept Biomed Informat, New York, NY USA

[17] Indiana Univ, Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA

[18] Childrens Minnesota, Minneapolis, MN USA

[19] Brigham Young Univ, Dept Publ Hlth, Provo, UT 84602 USA

来源：

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2022年 / 71卷 / 29期

关键词：

INFECTION;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：931 / 939

页数：9

共 50 条

[21] Phylogenetic, Sequencing, and Mutation Analysis of SARS-CoV-2 Omicron (BA.1) and Its Subvariants (BA.1.1, BA.2) During the Fifth Wave of the COVID-19 Pandemic in the Iraqi Kurdistan Region
Taher, Sherzad M.
Abdo, Jassim M.
Merza, Muayad A.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
[22] Comparative subgenomic mRNA profiles of SARS-CoV-2 Alpha, Delta and Omicron BA.1, BA.2 and BA.5 sub-lineages using Danish COVID-19 genomic surveillance data
Tang, Man-Hung Eric
Ng, Kim Lee
Edslev, Sofie Marie
Ellegaard, Kirsten
Stegger, Marc
Alexandersen, Soren
EBIOMEDICINE, 2023, 93
[23] Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 polymerase chain reaction positivity: primary, contributing, or incidental COVID-19
in't Holt, Anne F. Voor
Haanappel, Cynthia P.
Rahamat-Langendoen, Janette
Molenkamp, Richard
van Nood, Els
van den Toorn, Leon M.
Peeters, Robin P.
van Rossum, Annemarie M. C.
Severin, Juliette A.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 665 - 668
[24] Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2
Plans-Rubio, Pedro
VACCINES, 2023, 11 (12)
[25] Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022
Britton, Amadea
Embi, Peter J.
Levy, Matthew E.
Gaglani, Manjusha
DeSilva, Malini B.
Dixon, Brian E.
Dascomb, Kristin
Patel, Palak
Schrader, Kristin E.
Klein, Nicola P.
Ong, Toan C.
Natarajan, Karthik
Hartmann, Emily
Kharbanda, Anupam B.
Irving, Stephanie A.
Dickerson, Monica
Dunne, Margaret M.
Raiyani, Chandni
Grannis, Shaun J.
Stenehjem, Edward
Zerbo, Ousseny
Rao, Suchitra
Han, Jungmi
Sloan-Aagard, Chantel
Griggs, Eric P.
Weber, Zachary A.
Murthy, Kempapura
Fadel, William F.
Grisel, Nancy
McEvoy, Charlene
Lewis, Ned
Barron, Michelle A.
Nanez, Juan
Reese, Sarah E.
Mamawala, Mufaddal
Valvi, Nimish R.
Arndorfer, Julie
Goddard, Kristin
Yang, Duck-Hye
Fireman, Bruce
Ball, Sarah W.
Link-Gelles, Ruth
Naleway, Allison L.
Tenforde, Mark W.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (42): : 1335 - 1342
[26] Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
Lau, Jonathan J.
Cheng, Samuel M. S.
Leung, Kathy
Lee, Cheuk Kwong
Hachim, Asmaa
Tsang, Leo C. H.
Yam, Kenny W. H.
Chaothai, Sara
Kwan, Kelvin K. H.
Chai, Zacary Y. H.
Lo, Tiffany H. K.
Mori, Masashi
Wu, Chao
Valkenburg, Sophie A.
Amarasinghe, Gaya K.
Lau, Eric H. Y.
Hui, David S. C.
Leung, Gabriel M.
Peiris, Malik
Wu, Joseph T.
NATURE MEDICINE, 2023, 29 (02) : 348 - +
[27] Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
Jonathan J. Lau
Samuel M. S. Cheng
Kathy Leung
Cheuk Kwong Lee
Asmaa Hachim
Leo C. H. Tsang
Kenny W. H. Yam
Sara Chaothai
Kelvin K. H. Kwan
Zacary Y. H. Chai
Tiffany H. K. Lo
Masashi Mori
Chao Wu
Sophie A. Valkenburg
Gaya K. Amarasinghe
Eric H. Y. Lau
David S. C. Hui
Gabriel M. Leung
Malik Peiris
Joseph T. Wu
Nature Medicine, 2023, 29 : 348 - 357
[28] Differences in Clinical Presentation of COVID-19 in Children Hospitalized During Domination of Early (BA.1, BA.2) and Late (BA.5, BA.2.75, BQ.1 and XBB.1.5) SARS-CoV-2 Omicron Subvariants
Pokorska-Spiewak, Maria
Pawlowska, Malgorzata
Ciechanowski, Przemyslaw
Peregrym, Michal
Dobrzeniecka, Anna
Sobolewska-Pilarczyk, Malgorzata
Franczak, Justyna
Majda-Stanislawska, Ewa
Szczepanska, Barbara
Zaleska, Izabela
Flisiak, Robert
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2024, 43 (02) : 149 - 154
[29] Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1-and BA.2-Predominant Periods in Japan: The VENUS Study
Mimura, Wataru
Ishiguro, Chieko
Maeda, Megumi
Murata, Fumiko
Fukuda, Haruhisa
OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (12):
[30] Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
Veneti, Lamprini
Boas, Hakon
Kristoffersen, Anja Brathen
Stalcrantz, Jeanette
Bragstad, Karoline
Hungnes, Olav
Storm, Margrethe Larsdatter
Aasand, Nina
Ro, Gunnar
Starrfelt, Jostein
Seppala, Elina
Kvale, Reidar
Vold, Line
Nygard, Karin
Buanes, Eirik Alnes
Whittaker, Robert
EUROSURVEILLANCE, 2022, 27 (04)

← 1 2 3 4 5 →